Follow The Filings

JAZZ Jazz Pharmaceuticals PLC

Health Care, filed as JAZZ PHARMACEUTICALS PLC (SHS USD), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

Bought by 1 manager in 2026 Q2

  • 3 Owners
  • Max 15.4%
  • $55M
  • 1 new 1 small

In 2026 Q2 Polen Capital Management opened a position in Jazz Pharmaceuticals.

Who owns this now

Largest portfolio weights among holders, up to 15.4% (Michael Krensavage, Krensavage Asset Management). Not free-float ownership.

  1. Michael Krensavage 15.4%
  2. Tweedy, Browne Co. Reduce 1.1%

Who owns JAZZ

Sorted by value, long equity only, as of 2026 Q2.

History
Michael Krensavage, Krensavage Asset Management 15.4% Hold 167,816 $40M History
Tweedy, Browne Co. 1.1% Small trim −0.1% 60,149 $14M History
Polen Capital Management <0.01% New <0.01% 1,858 $448K History

3 current, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by JAZZ's executives, directors and 10% owners in the last 12 months, from their Form 4s

All JAZZ insider trades
  • None no insider bought on the open market
  • $35.3M sold by 8 insiders outside a trading plan
  • $33.2M sold by 5 insiders under 10b5-1 plans
  1. Renee D Gala CEO
    Planned sale
    $473K 2,000 shares at $236.40 1.4% of stake
    Traded Oct 6 Filed Oct 7
    ↗
  2. Bruce C Cozadd Director
    Planned sale
    $1.4M 6,000 shares at $230.33 1.7% of stake
    Traded Oct 1 Filed Oct 5
    ↗
  3. Neena M Patil EVP & Chief Legal Officer
    Planned sale
    $289K 1,200 shares at $240.94 2.5% of stake
    Traded Sep 10 Filed Sep 14
    ↗
  4. Renee D Gala CEO
    Planned sale
    $486K 2,000 shares at $243.03 1.4% of stake
    Traded Sep 8 Filed Sep 10
    ↗
  5. Bruce C Cozadd Director
    Planned sale
    $1.5M 6,000 shares at $250.13 1.7% of stake
    Traded Sep 1 Filed Sep 2
    ↗
  6. Robert Iannone EVP, Global Head of R&D & CMO
    Planned sale
    $19.2M 76,921 shares at $249.70 54% of stake
    Traded Aug 27 Filed Aug 31
    ↗
  7. Bruce C Cozadd Director
    Planned sale
    $1.5M 6,000 shares at $252.98 1.6% of stake
    Traded Aug 3 Filed Aug 5
    ↗
  8. Bruce C Cozadd Director
    Planned sale
    $1.4M 6,000 shares at $240.47 1.6% of stake
    Traded Jul 1 Filed Jul 6
    ↗
  9. Mark Douglas Smith Director
    Planned sale
    $267K 1,157 shares at $230.55 11% of stake
    Traded Jun 15 Filed Jun 17
    ↗
  10. Neena M Patil EVP & Chief Legal Officer
    Planned sale
    $278K 1,200 shares at $231.83 2.3% of stake
    Traded Jun 10 Filed Jun 12
    ↗
  11. Bruce C Cozadd Director
    Planned sale
    $1.4M 6,000 shares at $235.12 1.6% of stake
    Traded Jun 1 Filed Jun 3
    ↗
  12. Samantha Pearce EVP, Chief Commercial Officer
    Sale
    $1.6M 6,907 shares at $235.41 12% of stake
    Traded May 28 Filed Jun 1
    ↗
  13. Neena M Patil EVP & Chief Legal Officer
    Planned sale
    $282K 1,192 shares at $236.97 2.2% of stake
    Traded May 28 Filed Jun 1
    ↗
  14. Heather Ann McSharry Director
    Sale
    $482K 2,000 shares at $241.00 9.8% of stake
    Traded May 22 Filed May 27
    ↗
  15. Rick E Winningham Director
    Sale
    $662K 2,741 shares at $241.57 22% of stake
    Traded May 22 Filed May 27
    ↗

Also filed in the last 12 months, not counted as buying or selling: 45 share withholdings for taxes, 27 stock grants, 17 option exercises, 2 sales back to the company, 2 sales to cover taxes, and 1 gift.

Congress

No member of Congress reported trading JAZZ in the last three years. 1 member listed it in 2025 annual reports.

All Congress trades

SEC filings

Recent issuer filings from EDGAR, 10 shown.

Filed Form Detail Links
8-K 2.02 Filing Doc
8-K 5.02 Filing Doc
8-K 1.01,2.03,9.01 Filing Doc
8-K 7.01 Filing Doc
8-K 1.01,2.03,3.02,8.01,9.01 Filing Doc
8-K 8.01 Filing Doc
8-K 7.01,9.01 Filing Doc
8-K 1.01,9.01 Filing Doc
SCHEDULE 13G — Filing Doc
10-Q Filing Doc

Source: SEC EDGAR submissions, updated 6 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $3.83B $4.07B $4.27B
Net income $414.83M $560.12M -$356.15M
Net margin * 10.8% 13.8% -8.3%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $3.44B $4.63B $4.17B
Total non-current assets * $7.96B $7.38B $7.49B
Total assets $11.39B $12.01B $11.66B
Total current liabilities $1.54B $1.04B $2.24B
Total equity $3.74B $4.09B $4.32B

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations $1.09B $1.4B $1.36B
Cash from investing -$0.163B -$0.508B -$1.51B
Cash from financing -$305.25M $20.52M -$873.38M
Net change in cash $0.625B $0.907B -$1.02B

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.